Recent Finacing
Recent Raise
reMYND is a clinical-stage biopharma operating a proprietary drug-discovery platform and dedicated CRO, developing first-in-class small molecules including ReS19-T for Alzheimer’s and ReS39 for diabetes.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at reMYND.
